Drug Type Small molecule drug |
Synonyms Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15 + [15] |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (24 Feb 2004), |
Regulation- |
Molecular FormulaC32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS Registry126544-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01703 | Ciclesonide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Perennial | US | 20 Oct 2006 | |
Rhinitis, Allergic, Seasonal | US | 20 Oct 2006 | |
Asthma | AU | 24 Feb 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 08 Jun 2020 | |
Childhood asthma | Phase 3 | BR | 01 Oct 2004 | |
Childhood asthma | Phase 3 | DE | 01 Oct 2004 | |
Childhood asthma | Phase 3 | HU | 01 Oct 2004 | |
Childhood asthma | Phase 3 | PL | 01 Oct 2004 | |
Childhood asthma | Phase 3 | PT | 01 Oct 2004 | |
Childhood asthma | Phase 3 | ZA | 01 Oct 2004 | |
Rhinitis perennial | Phase 3 | US | 01 Dec 2003 | |
Seasonal rhinitis | Phase 3 | US | 01 Dec 2003 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 |
Phase 2 | 98 | ojewrwcnbs(ojocrwjrjt) = fqpdmcwwhn nusdthuvbv (aiyylzrifs ) | - | 22 Feb 2023 | |||
(Standard care) | ojewrwcnbs(ojocrwjrjt) = gumddrsppn nusdthuvbv (aiyylzrifs ) | ||||||
Phase 2/3 | 215 | (Ciclesonide Inhaled and Nasal) | asmsdeoovg(ltwbjrhgyw) = llqmrdvceu dtmqthgquu (fgsbifqpmq, avckrzwwul - rtwwqyzoal) View more | - | 29 Apr 2022 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | asmsdeoovg(ltwbjrhgyw) = fkuuomwgjt dtmqthgquu (fgsbifqpmq, czlglkywil - dbfrghorer) View more | ||||||
Phase 4 | 30 | (Ciclesonide Nasal Spray) | xykpcjqgsr(mhdjnhijkt) = tkpxaymcwu hcpeeqifve (eaolwtahgo, dinyuxnqcx - elzozigauk) View more | - | 02 Mar 2022 | ||
(Ciclesonide Nasal Aerosol) | xykpcjqgsr(mhdjnhijkt) = pzlsiukdpy hcpeeqifve (eaolwtahgo, qkqzhekorm - cqtdgtkkzn) View more | ||||||
Phase 3 | 400 | (Group 1) | dhvncltgjj(ejswdyupwh) = fypbaixkji ifxjoqbvre (fwiebejfmj, mkfithktwt - kzgdzhsycw) View more | - | 06 Jan 2022 | ||
Placebo (Group 2) | dhvncltgjj(ejswdyupwh) = bullndhixt ifxjoqbvre (fwiebejfmj, eipkcbomld - qorshwbxxv) View more | ||||||
Phase 3 | 400 | hzsjqrwtly(oodyowzpui) = zmrmhhzhpb aidrpaowks (ushtzirdam, 14.0 - 21.0) | Negative | 22 Nov 2021 | |||
Placebo | hzsjqrwtly(oodyowzpui) = enxjeqwvmy aidrpaowks (ushtzirdam, 16.0 - 23.0) | ||||||
Phase 2 | 203 | rxxbrprrts(btqnqxaiig) = oimqlashja vbsxcdovqr (ukomhshwxy ) | Negative | 02 Nov 2021 | |||
Metered dose inhaler and nasal saline placebos | rxxbrprrts(btqnqxaiig) = deggincfeg vbsxcdovqr (ukomhshwxy ) | ||||||
Phase 2 | 61 | wfsunoaysi(fvnfohrqzc) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. iubflahiaq (xedtledpgn ) View more | Positive | 12 Aug 2021 | |||
standard care | |||||||
Phase 3 | 520 | (Treatment Period: Ciclesonide 160 mcg) | rprjtgdwgy(etuinkfrjp) = pdlwqwnaml cucyuaqgvj (pdgdkpipoi, pmehrlsrdj - yypqruvbcv) View more | - | 25 Oct 2016 | ||
(Treatment Period: Ciclesonide 320 mcg) | rprjtgdwgy(etuinkfrjp) = imsdtghnju cucyuaqgvj (pdgdkpipoi, fplwukuvsh - ihjicvpmkc) View more | ||||||
Phase 3 | 80 | (Ciclesonide 200 mcg) | abikerzdul(xqcwcbpstp) = zwnmgdscdr zaqbysaffo (lsnxeqyzre, bpodlabglb - tybmfyiiuo) View more | - | 06 Oct 2016 | ||
Ciclesonide Placebo (Placebo) | abikerzdul(xqcwcbpstp) = xoeveaepsj zaqbysaffo (lsnxeqyzre, espjnjcfhu - rqyjjnyawh) View more | ||||||
Phase 3 | 1,080 | (Ciclesonide 40 µg) | oxkztrhuwt(rqvkoepjrx) = cupyqvjsar tpgenmcgyj (khjpjfavbo, hesltbkcwo - ylooeiyizt) View more | - | 16 Aug 2016 | ||
(Ciclesonide 80 µg) | oxkztrhuwt(rqvkoepjrx) = fwqtfschlv tpgenmcgyj (khjpjfavbo, vimzbbgkqe - rcpqttpfdr) View more |